Abstract

6-Azauracil was studied in patients with "advanced" acute leukemia, refractory to standard chemotherapy. Under the conditions of the study this compound was found to have no significant antileukemic activity. As a result, these data have defined the natural history of this phase of acute leukemia. A significant proportion (30 per cent) of these patients showed objective hematologic improvement even in the absence of effective specific therapy, which might be ascribed to a prospective new agent. The median survival from the onset of the study of this group of patients was two months, and survival patterns for adults and children were similar.

This content is only available as a PDF.